02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
22:04 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting GIP receptor could help treat MI. In a mouse model of MI, cardiomyocyte-specific knockout of GIP receptor increased survival and decreased left ventricular remodeling and scar formation...
22:58 , Oct 6, 2017 |  BioCentury  |  Emerging Company Profile

Metabolic contrarian

Antag Therapeutics ApS is going against the grain, blocking rather than boosting the effects of glucose-dependent insulinotropic polypeptide to treat obesity and diabetes. While several other companies are developing agonists to enhance the peptide’s glucose-regulating...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
20:42 , Jun 28, 2017 |  BC Extra  |  Financial News

Novo Seeds invests €2.7M in Antag

Metabolic start-up Antag Therapeutics ApS (Copenhagen, Denmark) said it has received a €2.7 million ($3 million) investment from Novo Seeds, the early stage investment arm of Novo Holdings A/S (Hellerup, Denmark). Antag is developing peptide...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Zealand Pharma preclinical data

In a mouse model of obesity, subcutaneous ZP-DI-70 every 3 days for 18 days reduced body weight by 4% at the 1 nmol/kg dose and by 13% at the 3 nmol/kg dose. In diabetic mice,...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucose-dependent insulinotropic polypeptide (GIP) receptor; glucagon-like peptide-1 receptor (GLP-1R; GLP1R); glucagon receptor (GCGR)

Endocrine/metabolic disease INDICATION: Obesity; diabetes Mouse studies suggest a monomeric peptide agonist of GIP receptor, GLP1R and GCGR could help treat obesity and diabetes. In a mouse model of diet-induced obesity, the triple agonist decreased...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity; diabetes Glucagon-like peptide-1 receptor (GLP-1R; GLP1R); glucagon receptor (GCGR); glucose-dependent insulinotropic polypeptide receptor (GIP receptor) Mouse studies suggest peptides that agonize GLP1R, GCGR...
07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms mAb antagonists against glucose-dependent insulinotropic polypeptide receptor (GIPR) mAb antagonists against GIPR could be useful as tools to develop improved inhibitors and study receptor function...
08:00 , Feb 25, 2013 |  BioCentury  |  Emerging Company Profile

Longevity: Internal Improvements

A handful of companies are using non-natural amino acids to improve the pharmacokinetic and metabolic profiles of peptides and proteins, but such modifications often alter the surface of the molecule, which can affect its binding...